


CERTIFICATE OF ANALYSIS (FINISHED PRODUCT)

(The Drugs & Cosmetics Act 1940 & Rules Made Thereunder)

Name of Sample	PIPRACAN INJECTION 4.5G	Certificate No.	BF-26080503
Generic Name	Piperacillin & Tazobactam for Injection IP	Receipt Date	05-08-2026
Mfd. By	Supermax Drugs & Pharmaceuticals Pvt. Ltd., Delhi-110040	Sample Qty	30 vials
Batch No.	PRCN-01	Batch Size	10100 vials
Mfg. Date	07/2026	Exp. Date	06/2028
Reference	IP (Indian Pharmacopoeia)	Mfg. Lic. No.	1829

ANALYSIS DATA		
Test	Results	Specification / Limits
CHEMICAL ANALYSIS		
Description	A white powder filled in colourless glass vials	A white powder filled in colourless glass vials
Average weight	4868.32mg	4401.0 mg to 5379.0 mg
*Identification	Complies	The retention times of the major peaks of the Sample solution correspond to those of the Standard solution, as obtained in the Assay.
Clarity of solution A.	After constitution of Injection the solid dissolves completely, leaving no visible residue as undissolved matter.	After constitution of Injection the solid should dissolves completely, leaving no visible residue as undissolved matter.
B.	The reconstituted injection is not significantly less clear than an equal volume of the Diluent or of water for injections contained in a similar container and examined in the same manner.	The reconstituted injection should not be significantly less clear than an equal volume of the Diluent or of water for injections contained in a similar container and examined in the same manner.
Particulate matter A. By Visual Inspection	The constituted solution is free from foreign particles that can be observed on visual inspection	The constituted solution should be free from foreign particles that can be observed on visual inspection
*B. By Light Obscuration Particle Count Test	246.0particles/Container 2.0 particles/Container	≥ 10 µm NMT 6000 particles/Container ≥ 25 µm NMT 600 particles/Container
*Related substances	Complies	To Comply
Uniformity of dosage Units	Within limit	Not more than two of the individual weight deviate from the average weight by more than 10% and non deviates by more than 20%.
pH	5.96	5.0 to 7.0
*Water	1.67% w/w	Not more than 2.5% w/w



Supermax Drugs & Pharmaceuticals Pvt. Ltd.

H-1231, DSIIDC Industrial Complex, Narela, Delhi – 110040

CERTIFICATE OF ANALYSIS (FINISHED PRODUCT)

(The Drugs & Cosmetics Act 1940 & Rules Made Thereunder)

Name of Sample	PIPRACAN INJECTION 4.5G	Certificate No.	BF-26080503
Generic Name	Piperacillin & Tazobactam for Injection IP	Receipt Date	05-08-2026
Mfd. By	Supermax Drugs & Pharmaceuticals Pvt. Ltd., Delhi-110040	Sample Qty	30 vials
Batch No.	PRCN-01	Batch Size	10100 vials
Mfg. Date	07/2026	Exp. Date	06/2028
Reference	IP (Indian Pharmacopoeia)	Mfg. Lic. No.	1829

***ASSAY / CONTENT:** Each vial on an average fill contains:


Ingredient	Result	Claim	Limit	Method
Piperacillin Sodium Eq. to Piperacillin	4027.14 mg	4000.0 mg	3600.0 mg to 4400.0 mg	IP
Tazobactam Sodium Eq. to Tazobactam	494.75 mg	500.0 mg	450.0 mg to 550.0 mg	IP

*BIOLOGICAL ANALYSIS

Sterility	Complies with the test for sterility. (Vide report no.- BSF-26072802 Date:-13-08-2026)	To Sterile
Bacterial endotoxins	Less than 0.08 EU/mg of Piperacillin & Tazobactam	Not more than 0.08 EU/mg of Piperacillin & Tazobactam

Remark: In the estimated the sample referred above is of standard quality as defined in the Act & Rules made thereunder as per IP.

*Indicate the results referred from the Vide report no. BSF-26072802 (B. No.- M-P4.5-48).

	ANALYZED BY	CHECKED BY	APPROVED BY
Name	Kundan Singh Bisht	Hari Om	Sumar Singh
Signature			
Date	13-08-2026	13-08-2026	13-08-2026
Designation	QC Chemist	QC Manager	QA Manager

